Doutremepuich C, Lalanne M C, Doutremepuich F, Walenga J, Fareed J, Breddin H K
Laboratoire d'Hématologie, C.J.F. INSERM, Bordeaux, France.
Haemostasis. 1991;21 Suppl 1:99-106. doi: 10.1159/000216269.
Three recombinant hirudins (r-hirudins) produced by genetic processes from Escherichia coli and yeast were studied. r-Hirudins could be an alternative treatment to heparin; so, the antithrombotic activity of these drugs should be compared to heparin, the reference substance, in an experimental venous thrombosis model. In this model, the effect of these r-hirudins on thrombus weight reduction were not identical. They varied depending on the original product (E. coli or yeast). The growth-inhibiting activity of r-hirudins on existing thrombi is not dose dependent, whereas that of heparin is. Moreover, in the conditions of this study, higher doses of heparin, but not of hirudins, increased the bleeding time. Although hirudin has limited applications for the time being, it seems an interesting anticoagulant drug, and the availability of r-hirudin opens new therapeutic anticoagulation perspectives.
对通过基因工程从大肠杆菌和酵母中生产的三种重组水蛭素（r-水蛭素）进行了研究。r-水蛭素可能是肝素的替代治疗药物；因此，应在实验性静脉血栓形成模型中将这些药物的抗血栓活性与作为参比物质的肝素进行比较。在该模型中，这些r-水蛭素对血栓重量减轻的作用并不相同。它们因原始产物（大肠杆菌或酵母）而异。r-水蛭素对现有血栓的生长抑制活性不依赖剂量，而肝素的生长抑制活性则依赖剂量。此外，在本研究条件下，较高剂量的肝素会增加出血时间，但r-水蛭素不会。尽管水蛭素目前的应用有限，但它似乎是一种有趣的抗凝药物，r-水蛭素的可得性为抗凝治疗开辟了新的前景。
